Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries’ one of subsidiary has entered into an agreement and plan of merger with InSite Vision Inc. (InSite Vision). InSite Vision focuses on developing new specialty ophthalmic products, including three late stage programs.

Sun Pharma is in the process of establishing a branded ophthalmic business in the US. This proposed acquisition of InSite Vision, coupled with the recent in-licensing of Xelpros (Latanoprost BAK-free eye drops) in June 2015, are steps in this direction. These deals give Sun Pharma access to four late stage branded ophthalmic products in the US.

Sun Pharma is the fifth largest specialty generic pharmaceutical company in the world. The company provides high quality, affordable medicines trusted by healthcare professionals and patients in over 150 countries worldwide.